Symbols / CAPR $32.11 +6.61% Capricor Therapeutics, Inc.
CAPR Chart
About
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.85B |
| Enterprise Value | 1.54B | Income | -105.04M | Sales | — |
| Book/sh | 5.33 | Cash/sh | 5.53 | Dividend Yield | — |
| Payout | 0.00% | Employees | 231 | IPO | — |
| P/E | — | Forward P/E | -84.50 | PEG | — |
| P/S | — | P/B | 6.02 | P/C | — |
| EV/EBITDA | -14.52 | EV/Sales | — | Quick Ratio | 8.88 |
| Current Ratio | 9.01 | Debt/Eq | 4.75 | LT Debt/Eq | — |
| EPS (ttm) | -2.26 | EPS next Y | -0.38 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -25.68% |
| ROE | -46.56% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 57.51M |
| Shs Float | 48.56M | Short Float | 14.16% | Short Ratio | 4.79 |
| Short Interest | — | 52W High | 40.37 | 52W Low | 4.30 |
| Beta | 0.48 | Avg Volume | 1.36M | Volume | 1.23M |
| Target Price | $53.90 | Recom | None | Prev Close | $30.12 |
| Price | $32.11 | Change | 6.61% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | B. Riley Securities | Buy → Buy | $63 |
| 2026-03-13 | reit | Piper Sandler | Overweight → Overweight | $58 |
| 2026-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-12-15 | reit | B. Riley Securities | Buy → Buy | $50 |
| 2025-12-10 | reit | Piper Sandler | Overweight → Overweight | $45 |
| 2025-12-08 | main | Oppenheimer | Outperform → Outperform | $54 |
| 2025-12-04 | main | Maxim Group | Buy → Buy | $50 |
| 2025-12-03 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-11-12 | main | Roth Capital | Buy → Buy | $13 |
| 2025-09-25 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-07-14 | main | Roth Capital | Buy → Buy | $12 |
| 2025-07-11 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-06-26 | init | B. Riley Securities | — → Buy | $21 |
| 2025-06-25 | main | Jones Trading | Buy → Buy | $29 |
| 2025-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
| 2025-06-23 | main | Oppenheimer | Outperform → Outperform | $22 |
| 2025-06-17 | reit | Roth Capital | Buy → Buy | $31 |
| 2025-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $77 |
- CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - MSN Wed, 01 Apr 2026 22
- Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - Stock Titan Fri, 03 Apr 2026 21
- Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - MarketBeat hu, 02 Apr 2026 15
- Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed? - simplywall.st Fri, 03 Apr 2026 08
- CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits Fri, 13 Mar 2026 20
- Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - Stock Traders Daily Sat, 04 Apr 2026 17
- CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - Yahoo Finance Fri, 05 Dec 2025 08
- Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - Stock Titan hu, 02 Apr 2026 20
- Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock - MarketBeat Fri, 03 Apr 2026 22
- Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - simplywall.st Sat, 04 Apr 2026 10
- Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance ue, 20 Jan 2026 08
- Capricor (NASDAQ: CAPR) EVP sells 25K shares after option exercises - Stock Titan hu, 02 Apr 2026 00
- Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - MarketBeat hu, 02 Apr 2026 15
- Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - Stock Titan hu, 02 Apr 2026 00
- Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - What's Next? - MarketBeat ue, 31 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
22.27
-11.55%
|
25.18
+886.81%
|
2.55
|
| Operating Revenue |
|
0.00
-100.00%
|
22.27
-11.55%
|
25.18
+886.81%
|
2.55
|
| Operating Expense |
|
108.14
+66.80%
|
64.83
+31.63%
|
49.26
+52.74%
|
32.25
|
| Research And Development |
|
84.45
+69.02%
|
49.97
+37.10%
|
36.45
+67.06%
|
21.82
|
| Selling General And Administration |
|
22.75
+60.05%
|
14.21
+14.95%
|
12.37
+19.83%
|
10.32
|
| General And Administrative Expense |
|
22.75
+60.05%
|
14.21
+14.95%
|
12.37
+19.83%
|
10.32
|
| Salaries And Wages |
|
15.53
+46.44%
|
10.61
+15.56%
|
9.18
+32.31%
|
6.94
|
| Other Gand A |
|
7.22
+100.04%
|
3.61
+13.20%
|
3.19
-5.77%
|
3.38
|
| Total Expenses |
|
108.14
+66.80%
|
64.83
+31.63%
|
49.26
+52.74%
|
32.25
|
| Operating Income |
|
-108.14
-154.07%
|
-42.56
-76.77%
|
-24.08
+18.92%
|
-29.70
|
| Total Operating Income As Reported |
|
-108.14
-154.07%
|
-42.56
-76.77%
|
-24.08
+18.92%
|
-29.70
|
| EBITDA |
|
-100.11
-156.42%
|
-39.04
-69.67%
|
-23.01
+21.11%
|
-29.16
|
| Normalized EBITDA |
|
-106.21
-158.22%
|
-41.13
-66.31%
|
-24.73
+16.59%
|
-29.65
|
| Reconciled Depreciation |
|
1.89
+32.54%
|
1.43
+33.34%
|
1.07
+100.49%
|
0.53
|
| EBIT |
|
-102.00
-152.06%
|
-40.47
-68.06%
|
-24.08
+18.92%
|
-29.70
|
| Total Unusual Items |
|
6.10
+191.84%
|
2.09
+21.33%
|
1.72
+253.53%
|
0.49
|
| Total Unusual Items Excluding Goodwill |
|
6.10
+191.84%
|
2.09
+21.33%
|
1.72
+253.53%
|
0.49
|
| Special Income Charges |
|
-0.16
-39.64%
|
-0.11
-1767.32%
|
-0.01
+82.37%
|
-0.03
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Pretax Income |
|
-105.04
-159.58%
|
-40.47
-81.56%
|
-22.29
+23.20%
|
-29.02
|
| Net Non Operating Interest Income Expense |
|
-3.05
|
0.00
|
—
|
—
|
| Interest Expense Non Operating |
|
3.05
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-3.05
|
0.00
|
—
|
—
|
| Interest Expense |
|
3.05
|
0.00
|
—
|
—
|
| Other Income Expense |
|
6.15
+192.97%
|
2.10
+17.17%
|
1.79
+164.12%
|
0.68
|
| Other Non Operating Income Expenses |
|
0.05
+507.96%
|
0.01
-88.96%
|
0.07
-64.50%
|
0.19
|
| Gain On Sale Of Security |
|
6.26
+184.05%
|
2.20
+27.44%
|
1.73
+231.46%
|
0.52
|
| Tax Provision |
|
0.00
+0.00%
|
0.00
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Net Income From Continuing And Discontinued Operation |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Net Income Continuous Operations |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Normalized Income |
|
-111.14
-161.16%
|
-42.56
-77.25%
|
-24.01
+18.63%
|
-29.51
|
| Net Income Common Stockholders |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Diluted EPS |
|
-2.26
-96.52%
|
-1.15
-38.55%
|
-0.83
+29.66%
|
-1.18
|
| Basic EPS |
|
-2.26
-96.52%
|
-1.15
-38.55%
|
-0.83
+29.66%
|
-1.18
|
| Basic Average Shares |
|
46.48
+31.97%
|
35.22
+31.52%
|
26.78
+9.06%
|
24.55
|
| Diluted Average Shares |
|
46.48
+31.97%
|
35.22
+31.52%
|
26.78
+9.06%
|
24.55
|
| Diluted NI Availto Com Stockholders |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Depreciation Amortization Depletion Income Statement |
|
0.94
+44.17%
|
0.65
+47.21%
|
0.44
+293.04%
|
0.11
|
| Depreciation And Amortization In Income Statement |
|
0.94
+44.17%
|
0.65
+47.21%
|
0.44
+293.04%
|
0.11
|
| Depreciation Income Statement |
|
—
|
0.65
+47.21%
|
0.44
+293.04%
|
0.11
|
| Gain On Sale Of PPE |
|
-0.16
-39.64%
|
-0.11
-1767.32%
|
-0.01
+82.37%
|
-0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
355.95
+108.79%
|
170.48
+190.26%
|
58.73
+17.25%
|
50.09
|
| Current Assets |
|
322.94
+97.66%
|
163.39
+221.27%
|
50.86
+18.58%
|
42.89
|
| Cash Cash Equivalents And Short Term Investments |
|
318.13
+109.96%
|
151.52
+283.70%
|
39.49
-4.67%
|
41.42
|
| Cash And Cash Equivalents |
|
287.85
+2450.26%
|
11.29
-23.19%
|
14.69
+53.02%
|
9.60
|
| Other Short Term Investments |
|
30.28
-78.41%
|
140.23
+465.60%
|
24.79
-22.08%
|
31.82
|
| Receivables |
|
0.06
-99.43%
|
10.37
-0.03%
|
10.37
+1794.15%
|
0.55
|
| Accounts Receivable |
|
0.06
-99.43%
|
10.37
-0.03%
|
10.37
+1794.15%
|
0.55
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
4.75
+216.59%
|
1.50
+50.73%
|
1.00
+8.25%
|
0.92
|
| Total Non Current Assets |
|
33.01
+365.20%
|
7.10
-9.94%
|
7.88
+9.33%
|
7.21
|
| Net PPE |
|
31.85
+363.33%
|
6.87
-9.68%
|
7.61
+9.70%
|
6.94
|
| Gross PPE |
|
37.00
+258.39%
|
10.32
+5.17%
|
9.82
+20.90%
|
8.12
|
| Accumulated Depreciation |
|
-5.15
-49.29%
|
-3.45
-56.39%
|
-2.21
-86.70%
|
-1.18
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.51
+164.82%
|
0.19
+2.17%
|
0.19
+34.92%
|
0.14
|
| Construction In Progress |
|
11.44
|
0.00
|
—
|
—
|
| Other Properties |
|
22.27
+191.84%
|
7.63
+1.75%
|
7.50
+13.85%
|
6.59
|
| Leases |
|
2.79
+11.36%
|
2.50
+17.48%
|
2.13
+52.82%
|
1.39
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
1.16
+423.00%
|
0.22
-17.33%
|
0.27
+0.00%
|
0.27
|
| Total Liabilities Net Minority Interest |
|
50.16
+100.48%
|
25.02
-30.76%
|
36.13
-5.68%
|
38.31
|
| Current Liabilities |
|
35.84
+70.44%
|
21.03
-32.76%
|
31.27
+32.57%
|
23.59
|
| Payables And Accrued Expenses |
|
17.21
+110.13%
|
8.19
+31.06%
|
6.25
+26.94%
|
4.92
|
| Payables |
|
1.65
-49.61%
|
3.28
-47.46%
|
6.25
+26.94%
|
4.92
|
| Accounts Payable |
|
1.65
-49.61%
|
3.28
-47.23%
|
6.22
+28.71%
|
4.83
|
| Current Accrued Expenses |
|
15.56
+217.01%
|
4.91
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.20
-75.76%
|
0.83
+11.44%
|
0.75
+9.83%
|
0.68
|
| Current Capital Lease Obligation |
|
0.20
-75.76%
|
0.83
+11.44%
|
0.75
+9.83%
|
0.68
|
| Current Deferred Liabilities |
|
12.00
+0.00%
|
12.00
-50.56%
|
24.27
+34.98%
|
17.98
|
| Current Deferred Revenue |
|
12.00
+0.00%
|
12.00
-50.56%
|
24.27
+34.98%
|
17.98
|
| Other Current Liabilities |
|
6.42
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
14.32
+258.68%
|
3.99
-17.90%
|
4.86
-66.97%
|
14.72
|
| Long Term Debt And Capital Lease Obligation |
|
14.32
+2223.55%
|
0.62
-58.55%
|
1.49
-20.83%
|
1.88
|
| Long Term Capital Lease Obligation |
|
14.32
+2223.55%
|
0.62
-58.55%
|
1.49
-20.83%
|
1.88
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
9.47
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
9.47
|
| Other Non Current Liabilities |
|
—
|
3.38
+0.00%
|
3.38
+0.00%
|
3.38
|
| Stockholders Equity |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Common Stock Equity |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Capital Stock |
|
0.06
+25.86%
|
0.05
+46.34%
|
0.03
+23.40%
|
0.03
|
| Common Stock |
|
0.06
+25.86%
|
0.05
+46.34%
|
0.03
+23.40%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
57.37
+25.86%
|
45.58
+46.34%
|
31.15
+23.40%
|
25.24
|
| Ordinary Shares Number |
|
57.37
+25.86%
|
45.58
+46.34%
|
31.15
+23.40%
|
25.24
|
| Additional Paid In Capital |
|
610.33
+77.31%
|
344.22
+89.44%
|
181.70
+22.16%
|
148.74
|
| Retained Earnings |
|
-304.88
-52.57%
|
-199.83
-25.39%
|
-159.37
-16.26%
|
-137.08
|
| Gains Losses Not Affecting Retained Earnings |
|
0.28
-72.43%
|
1.03
+335.50%
|
0.24
+124.06%
|
0.11
|
| Other Equity Adjustments |
|
0.28
-72.43%
|
1.03
+335.50%
|
0.24
+124.06%
|
0.11
|
| Total Equity Gross Minority Interest |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Total Capitalization |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Working Capital |
|
287.10
+101.68%
|
142.36
+626.85%
|
19.59
+1.47%
|
19.30
|
| Invested Capital |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Total Debt |
|
14.52
+900.80%
|
1.45
-35.10%
|
2.24
-12.66%
|
2.56
|
| Capital Lease Obligations |
|
14.52
+900.80%
|
1.45
-35.10%
|
2.24
-12.66%
|
2.56
|
| Net Tangible Assets |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Tangible Book Value |
|
305.79
+110.22%
|
145.46
+543.60%
|
22.60
+91.76%
|
11.79
|
| Dueto Related Parties Current |
|
—
|
—
|
0.03
-69.21%
|
0.09
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-69.81
-74.55%
|
-40.00
-56.25%
|
-25.60
-620.61%
|
4.92
|
| Cash Flow From Continuing Operating Activities |
|
-69.81
-74.55%
|
-40.00
-56.25%
|
-25.60
-620.61%
|
4.92
|
| Net Income From Continuing Operations |
|
-105.04
-159.58%
|
-40.47
-81.57%
|
-22.29
+23.20%
|
-29.02
|
| Depreciation Amortization Depletion |
|
1.89
+32.54%
|
1.43
+33.34%
|
1.07
+100.49%
|
0.53
|
| Depreciation |
|
1.89
+32.54%
|
1.43
+33.34%
|
1.07
+100.49%
|
0.53
|
| Amortization Cash Flow |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization |
|
1.89
+32.54%
|
1.43
+33.34%
|
1.07
+100.49%
|
0.53
|
| Amortization Of Intangibles |
|
—
|
—
|
—
|
0.00
|
| Other Non Cash Items |
|
3.76
+8058.33%
|
-0.05
-94.63%
|
-0.02
-115.01%
|
0.16
|
| Stock Based Compensation |
|
17.23
+76.39%
|
9.77
+32.10%
|
7.39
+65.80%
|
4.46
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
0.16
+39.64%
|
0.11
+1767.32%
|
0.01
-82.37%
|
0.03
|
| Gain Loss On Sale Of PPE |
|
0.16
+39.64%
|
0.11
+1767.32%
|
0.01
-82.37%
|
0.03
|
| Change In Working Capital |
|
12.20
+213.12%
|
-10.78
+8.23%
|
-11.75
-140.88%
|
28.75
|
| Change In Receivables |
|
10.31
+294115.81%
|
0.00
+100.04%
|
-9.82
-6204.57%
|
-0.16
|
| Change In Prepaid Assets |
|
-4.09
-792.53%
|
-0.46
-504.41%
|
-0.08
-131.61%
|
0.24
|
| Change In Payables And Accrued Expense |
|
5.98
+208.27%
|
1.94
+46.35%
|
1.33
+9.78%
|
1.21
|
| Change In Payable |
|
—
|
—
|
1.33
+9.78%
|
1.21
|
| Change In Account Payable |
|
—
|
—
|
1.33
+9.78%
|
1.21
|
| Change In Other Working Capital |
|
—
|
-12.27
-286.10%
|
-3.18
-111.58%
|
27.45
|
| Change In Other Current Assets |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
97.48
+183.90%
|
-116.18
-2374.45%
|
5.11
+114.56%
|
-35.07
|
| Cash Flow From Continuing Investing Activities |
|
97.48
+183.90%
|
-116.18
-2374.45%
|
5.11
+114.56%
|
-35.07
|
| Net PPE Purchase And Sale |
|
-11.72
-661.82%
|
-1.54
+24.84%
|
-2.05
+39.06%
|
-3.36
|
| Purchase Of PPE |
|
-11.72
-661.82%
|
-1.54
+24.84%
|
-2.05
+39.06%
|
-3.36
|
| Capital Expenditure |
|
-11.72
-661.82%
|
-1.54
+24.84%
|
-2.05
+39.06%
|
-3.36
|
| Net Investment Purchase And Sale |
|
109.20
+195.25%
|
-114.64
-1702.14%
|
7.16
+122.56%
|
-31.71
|
| Purchase Of Investment |
|
-151.39
+27.37%
|
-208.44
-113.91%
|
-97.44
+14.69%
|
-114.22
|
| Sale Of Investment |
|
260.60
+177.83%
|
93.80
-10.33%
|
104.60
+26.78%
|
82.51
|
| Financing Cash Flow |
|
248.89
+62.92%
|
152.77
+497.23%
|
25.58
+424.84%
|
4.87
|
| Cash Flow From Continuing Financing Activities |
|
248.89
+62.92%
|
152.77
+497.23%
|
25.58
+424.84%
|
4.87
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
237.03
+55.61%
|
152.32
+496.98%
|
25.52
+431.18%
|
4.80
|
| Proceeds From Stock Option Exercised |
|
11.86
+2534.18%
|
0.45
+596.85%
|
0.06
-8.11%
|
0.07
|
| Changes In Cash |
|
276.56
+8215.36%
|
-3.41
-166.93%
|
5.09
+120.14%
|
-25.28
|
| Beginning Cash Position |
|
11.29
-23.19%
|
14.69
+53.02%
|
9.60
-72.47%
|
34.89
|
| End Cash Position |
|
287.85
+2450.26%
|
11.29
-23.19%
|
14.69
+53.02%
|
9.60
|
| Free Cash Flow |
|
-81.54
-96.31%
|
-41.53
-50.25%
|
-27.64
-1875.58%
|
1.56
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
237.03
+55.61%
|
152.32
+496.98%
|
25.52
+431.18%
|
4.80
|
| Issuance Of Capital Stock |
|
237.03
+55.61%
|
152.32
+496.98%
|
25.52
+431.18%
|
4.80
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-01 View
- 42026-04-01 View
- 42026-04-01 View
- 42026-03-27 View
- 10-K2026-03-17 View
- 8-K2026-03-12 View
- 8-K2026-03-10 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42026-01-07 View
- 42025-12-23 View
- 8-K2025-12-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|